The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Open accessAbstract
Summary Broadly neutralizing antibodies (bNAbs) against HIV-1 provide both effective pre-exposure prophylaxis and treatment of HIV-1 infection in murine and non-human primate models, suggesting their potential use in humans. While much is known about the role of variable domains in the neutralization breadth and potency of these bNAbs, the contribution of Fc domains to their activities is, by contrast, poorly characterized. Assessment of the in vivo activity of several bNAbs revealed that FcγR-mediated effector function contributes substantially to their capacity to block viral entry, suppress viremia and confer therapeutic activity. Enhanced in vivo potency of anti-HIV-1 bNAbs was associated with preferential engagement of activating, but not inhibitory FcγRs and Fc domain-engineered bNAb variants with selective binding capacity for activating FcγRs displayed augmented protective activity. These findings reveal key roles for Fc effector function in the in vivo activity of anti-HIV-1 bNAbs and provide novel strategies for generating bNAbs with improved efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Predominant Autoantibody Production by Early Human B Cell Precursors
Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., & Nussenzweig, M. C. (2003) · Science · doi:10.1126/science.1086907 · Cited by 2,083
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Broad neutralization coverage of HIV by multiple highly potent antibodies
Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480
Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., et al. (2000) · Nature Medicine · doi:10.1038/72318 · Cited by 1,250
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011) · Science · doi:10.1126/science.1207227 · Cited by 1,139
Self-citationDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Self-citationDevelopment of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice
Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.-C., Lanzavecchia, A., & Manz, M. G. (2004) · Science · doi:10.1126/science.1093933 · Cited by 993
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G., Anthony, R. M., Zebroski, H., Hurley, A., et al. (2009) · Nature · doi:10.1038/nature07930 · Cited by 867
Self-citationEngineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749
Self-citationA Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., et al. (2011) · Science · doi:10.1126/science.1213256 · Cited by 694
Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Self-citationEvaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays
Montefiori, D. C. (2004) · Current Protocols in Immunology · doi:10.1002/0471142735.im1211s64 · Cited by 580
Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies
Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J. F., Halper-Stromberg, A., Gnanapragasam, P. N. P., Spencer, D. I. R., Seaman, M. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217207109 · Cited by 550
Self-citationAntibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Self-citationHIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Klein, F., Halper-Stromberg, A., Horwitz, J. A., Gruell, H., Scheid, J. F., Bournazos, S., Mouquet, H., Spatz, L. A., Diskin, R., Abadir, A., et al. (2012) · Nature · doi:10.1038/nature11604 · Cited by 500
Self-citationAntibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Self-citationAntibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O. K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M., Lifson, J. D., et al. (2013) · Nature · doi:10.1038/nature12746 · Cited by 455
Self-citationHalper-Stromberg, A., Lu, C.-L., Klein, F., Horwitz, J. A., Bournazos, S., Nogueira, L., Eisenreich, T. R., Liu, C., Gazumyan, A., Schaefer, U., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.043 · Cited by 381
Self-citationIncreasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design
Diskin, R., Scheid, J. F., Marcovecchio, P. M., West, A. P., Klein, F., Gao, H., Gnanapragasam, P. N. P., Abadir, A., Seaman, M. S., Nussenzweig, M. C., et al. (2011) · Science · doi:10.1126/science.1213782 · Cited by 375
Self-citationLi, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Self-citationMouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 307
Self-citationHorwitz, J. A., Halper-Stromberg, A., Mouquet, H., Gitlin, A. D., Tretiakova, A., Eisenreich, T. R., Malbec, M., Gravemann, S., Billerbeck, E., Dorner, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315295110 · Cited by 271
Self-citationBaenziger, S., Tussiwand, R., Schlaepfer, E., Mazzucchelli, L., Heikenwalder, M., Kurrer, M. O., Behnke, S., Frey, J., Oxenius, A., Joller, H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604493103 · Cited by 242
FcγRI-Deficient Mice Show Multiple Alterations to Inflammatory and Immune Responses
Barnes, N., Gavin, A. L., Tan, P. S., Mottram, P., Koentgen, F., & Hogarth, P. M. (2002) · Immunity · doi:10.1016/s1074-7613(02)00287-x · Cited by 207
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
Nimmerjahn, F., Lux, A., Albert, H., Woigk, M., Lehmann, C., Dudziak, D., Smith, P., & Ravetch, J. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014515107 · Cited by 200
Self-citationKlein, F., Gaebler, C., Mouquet, H., Sather, D. N., Lehmann, C., Scheid, J. F., Kraft, Z., Liu, Y., Pietzsch, J., Hurley, A., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120423 · Cited by 159
Self-citationFcγRIIa Genotype Predicts Progression of HIV Infection
Forthal, D. N., Landucci, G., Bream, J. H., Jacobson, L. P., Phan, T. B., & Montoya, B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7916 · Cited by 153
Forthal, D. N., Gach, J. S., Landucci, G., Jeż, J., Strasser, R., Kunert, R., & Steinkellner, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002600 · Cited by 145
Datta‐Mannan, A., Witcher, D. R., Tang, Y., Watkins, J. D., Jiang, W., & Wroblewski, V. J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011734 · Cited by 136
Moldt, B., Shibata‐Koyama, M., Rakasz, E. G., Schultz, N., Kanda, Y., Dunlop, D. C., Finstad, S. L., Jin, C., Landucci, G., Alpert, M. D., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00491-12 · Cited by 122
Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies
Diskin, R., Klein, F., Horwitz, J. A., Halper-Stromberg, A., Sather, D. N., Marcovecchio, P., Lee, T., West, A. P., Gao, H., Seaman, M. S., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130221 · Cited by 110
Self-citationA requirement for FcγR in antibody-mediated bacterial toxin neutralization
Abboud, N., Chow, S.-K., Saylor, C., Markmann, A. J., Ravetch, J. V., Scharff, M. D., & Casadevall, A. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100995 · Cited by 109
Self-citationZhang, Y., Hatziioannou, T., Zang, T. M., Braaten, D. C., Luban, J., Goff, S. P., & Bieniasz, P. D. (2002) · Journal of Virology · doi:10.1128/jvi.76.12.6332-6343.2002 · Cited by 108
Heider, K., Kiefer, K., Zenz, T., Volden, M., Stilgenbauer, S., Ostermann, E., Baum, A., Lamche, H. R., Küpcü, Z., Jacobi, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351932 · Cited by 104
Ackerman, M. E., Dugast, A., McAndrew, E. G., Tsoukas, S., Licht, A. F., Irvine, D. J., & Alter, G. (2013) · Journal of Virology · doi:10.1128/jvi.03403-12 · Cited by 102
Translating basic mechanisms of IgG effector activity into next generation cancer therapies.
Nimmerjahn, F., & Ravetch, J. V. (2012) · Europe PMC (PubMed Central) · Cited by 88
Self-citationPietzsch, J., Gruell, H., Bournazos, S., Donovan, B. M., Klein, F., Diskin, R., Seaman, M. S., Björkman, P. J., Ravetch, J. V., Ploß, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213409109 · Cited by 82
Self-citationPietzsch, J., Scheid, J. F., Mouquet, H., Klein, F., Seaman, M. S., Janković, M., Corti, D., Lanzavecchia, A., & Nussenzweig, M. C. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101176 · Cited by 67
Self-citationHuman IgG Fc domain engineering enhances antitoxin neutralizing antibody activity
Bournazos, S., Chow, S.-K., Abboud, N., Casadevall, A., & Ravetch, J. V. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72676 · Cited by 66
Self-citationDugast, A., Chan, Y. N., Hoffner, M., Licht, A. F., Nkolola, J. P., Li, H., Streeck, H., Suscovich, T. J., Ghebremichael, M. S., Ackerman, M. E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097229 · Cited by 65
Immunoglobulin isotype influences affinity and specificity
Casadevall, A., & Markmann, A. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209750109 · Cited by 54
Cited by
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Caskey, M., Klein, F., Lorenzi, J. C. C., Seaman, M. S., West, A. P., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J. F., et al. (2015) · Nature · doi:10.1038/nature14411 · Cited by 767
Self-citationThe role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
Self-citationBroadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
Burton, D. R., & Hangartner, L. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055515 · Cited by 583
Mouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 579
Metadata
- Authors
- Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 158
- Issue
- 6
- Pages
- 1243-1253
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W1985136634
- Cited by
- 493
- References
- 46
- FWCI
- 22.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.